Soo Han Kim1, Jae Won Lee2, Jung-Min Ahn3, Dae-Hee Kim3, Jong-Min Song3, Sang-Do Lee4, Jae Seung Lee4. 1. Department of Internal Medicine, Center for Pulmonary Hypertension and Venous Thrombosis, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 2. Department of Thoracic and Cardiovascular Surgery, Center for Pulmonary Hypertension and Venous Thrombosis, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 3. Department of Cardiology, Center for Pulmonary Hypertension and Venous Thrombosis, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 4. Department of Pulmonary and Critical Care Medicine, Center for Pulmonary Hypertension and Venous Thrombosis, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Abstract
BACKGROUND/AIMS: Pulmonary endarterectomy (PEA) is the gold standard for treating chronic thromboembolic pulmonary hypertension (CTEPH) in Western countries. The aim of this study was to investigate the long-term outcomes of performing PEA on CTEPH patients in comparison with medical therapy at a single Korean center. METHODS: This retrospective study included 88 CTEPH patients. These patients were classified into the PEA group (n = 37) or non-PEA group (i.e., medical therapy; n = 51). The clinical characteristics, hemodynamic data, and long-term survival rates were compared. Independent prognostic factors for CTEPH were also investigated. RESULTS: CTEPH was not associated with either gender, and the mean age at diagnosis was 53.3 ± 13.7 years. Echocardiography revealed that the mean peak velocity of the tricuspid regurgitation jet was 4.2 ± 0.7 m/sec and the mean pulmonary arterial pressure was 51.7 ± 15.1 mmHg. The PEA and non-PEA groups demonstrated no significant differences, except in terms of the right ventricular end-diastolic diameter. The survival rates of the PEA group were significantly higher than the non-PEA group at 1, 3, 5, and 10 years (p = 0.032). Multivariate analyses indicated that World Health Organization class IV and PEA were significant predictors of poorer and better outcomes, respectively. CONCLUSIONS: PEA demonstrates more favorable effects on long-term survival than medical therapy in Korean CTEPH patients who were considered operable.
BACKGROUND/AIMS: Pulmonary endarterectomy (PEA) is the gold standard for treating chronic thromboembolic pulmonary hypertension (CTEPH) in Western countries. The aim of this study was to investigate the long-term outcomes of performing PEA on CTEPHpatients in comparison with medical therapy at a single Korean center. METHODS: This retrospective study included 88 CTEPHpatients. These patients were classified into the PEA group (n = 37) or non-PEA group (i.e., medical therapy; n = 51). The clinical characteristics, hemodynamic data, and long-term survival rates were compared. Independent prognostic factors for CTEPH were also investigated. RESULTS:CTEPH was not associated with either gender, and the mean age at diagnosis was 53.3 ± 13.7 years. Echocardiography revealed that the mean peak velocity of the tricuspid regurgitation jet was 4.2 ± 0.7 m/sec and the mean pulmonary arterial pressure was 51.7 ± 15.1 mmHg. The PEA and non-PEA groups demonstrated no significant differences, except in terms of the right ventricular end-diastolic diameter. The survival rates of the PEA group were significantly higher than the non-PEA group at 1, 3, 5, and 10 years (p = 0.032). Multivariate analyses indicated that World Health Organization class IV and PEA were significant predictors of poorer and better outcomes, respectively. CONCLUSIONS:PEA demonstrates more favorable effects on long-term survival than medical therapy in Korean CTEPHpatients who were considered operable.
Authors: Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: Michael M Madani; William R Auger; Victor Pretorius; Naohide Sakakibara; Kim M Kerr; Nick H Kim; Peter F Fedullo; Stuart W Jamieson Journal: Ann Thorac Surg Date: 2012-05-23 Impact factor: 4.330
Authors: Joanna Pepke-Zaba; Marion Delcroix; Irene Lang; Eckhard Mayer; Pavel Jansa; David Ambroz; Carmen Treacy; Andrea M D'Armini; Marco Morsolini; Repke Snijder; Paul Bresser; Adam Torbicki; Bent Kristensen; Jerzy Lewczuk; Iveta Simkova; Joan A Barberà; Marc de Perrot; Marius M Hoeper; Sean Gaine; Rudolf Speich; Miguel A Gomez-Sanchez; Gabor Kovacs; Abdul Monem Hamid; Xavier Jaïs; Gérald Simonneau Journal: Circulation Date: 2011-10-03 Impact factor: 29.690
Authors: Robin Condliffe; David G Kiely; J Simon R Gibbs; Paul A Corris; Andrew J Peacock; David P Jenkins; Denise Hodgkins; Kim Goldsmith; Rodney J Hughes; Karen Sheares; Steven S L Tsui; Iain J Armstrong; Chantal Torpy; Rachel Crackett; Christopher M Carlin; Clare Das; J Gerry Coghlan; Joanna Pepke-Zaba Journal: Am J Respir Crit Care Med Date: 2008-02-21 Impact factor: 21.405
Authors: John D L Brookes; Crystal Li; Sally T W Chung; Elizabeth M Brookes; Michael L Williams; Nicholas McNamara; Sofia Martin-Suarez; Antonio Loforte Journal: Ann Cardiothorac Surg Date: 2022-03